Our results highlight the regulatory potential of CD39/CD73-expressing B cells in pediatric IBD and suggest CD39<sup>+</sup> plasmablasts as a potential determinant of a successful immunosuppressive therapy with IFX. Here, ENTPD1 is linked to inflammatory bowel disease.